Scouting report · NKTR
Howard W. Robin
Nektar's President & CEO since January 2007; earlier Sirna CEO and Berlex CFO
- Born / age
- (73)
- Role
- President & CEO; director
- In the role
- 20 yr
- Education
- BS Fairleigh Dickinson University
- Front Office rank
- not ranked yet
NKTR
Stake value—no holding or price on file
—thin record
Scouting sheetas of 25 Sep 2026
Delivers guidance—no promises on the record yet
Answers the question—no call reviewed yet
Capital allocation—company not reviewed yet
Pay design40strategic, time only · 99.1% for · company lost money
Skin in the game—no holding or price on file
—Hit rate
—Pay at risk
99%Say-on-pay
—Airtime on calls
- Beat
- 0
- Met
- 0
- Missed
- 0
- Withdrawn
- 0
- Still open
- 0
- Answers on calls
- 0
- Questions dodged
- 0
- Dodges / 100 answers
- —
Personal and ownership data
What to weigh
Red flag 1
- Pay-versus-performance table: $100 invested at end-2020 was worth $16.58 at end-2025 against $124.75 for the peer index; GAAP net loss $164m in 2025 and every year shownsrc
Watch 5
- Re-elected in June 2026 with about 72.6% of votes cast for (13.16m for, 4.98m against), a weak result for a sole nomineesrc
- Change-of-control plan (2006) gives him 24 months of salary plus target bonus, full equity acceleration and a grandfathered excise-tax gross-upsrc
- Bonus pays on a board-scored corporate rating (75% rezpegaldesleukin milestones). 2025 raw score was 90-96%; the board lifted it to 100% for goals not set at the start of the year, with the financial goal scored zerosrc
- Sold 20,000 shares on 2026-06-16/17 (about $1.2m) under a 10b5-1 plan adopted 2026-03-13src
- Also sold about 20,000 shares on 2025-09-02/04/05/09 under an earlier 10b5-1 plan, as the stock ran from about $30 to $48 after the Phase 2b datasrc
Pay
Salary and otherBonus, stock, options, incentive
The table
- Bonus pays on
- Cash bonus target 100% of salary, paid solely on the board's corporate performance rating (2025: rezpegaldesleukin 75%, NKTR-0165/0166 10%, financial/BD 15%); paid at 100%
- Long-term award pays on
- December 2025 grant: 86,667 time-based options and 21,667 time-based RSUs (four-year vesting) plus 21,667 performance RSUs that vest only on full enrollment of both Phase 3 atopic dermatitis monotherapy studies within four yearssrc
- Pay at risk not on file
- Pays on returns strategic, time only
- Shareholder vote 99.1% for
- Pay vs profit company lost money
Career
- 2007 – nowNektar Therapeuticssrc
President & CEO; director since February 2007
Took over in January 2007; has run the company through the bempegaldesleukin (oncology) programme's 2022 failure and the pivot to immunology (rezpegaldesleukin) - 2001 – 2006Sirna Therapeuticssrc
President & CEO and director (Jul 2001-Nov 2006); COO, President and director (Jan-Jun 2001)
RNAi company later acquired by Merck (DEF14A-2026) - 1991 – 2001Berlex Laboratories (U.S. subsidiary of Schering AG)src
Corporate Vice President and General Manager, therapeutics division
Responsible for Betaseron and Fludara per DEF14A-2026 - 1987 – 1991
- 1984 – 1987
Undated in the sources
- Arthur Andersen & Co.src, Senior Associate
Not located: Arthur Andersen years not stated; December 2006 between Sirna and Nektar not described
The promise ledger
No promise on the record yet: the research routine has not scored this company's guidance.
Background
- Family The 2026 proxy counts 28 shares held by his spouse in his beneficial ownership. Neither the 2026 proxy nor the FY2025 10-K carries an Item 401(d) family-relationship statementsrc
- Boards Former member of the Fairleigh Dickinson University Board of Trustees (the 2021 proxy said he was serving; the 2026 proxy says previously)src
- Boards Former outside boards per the search summary: Inogen (2015-2021), Sientra (2014-2018), Versartis (2014-2018), Auspex Pharmaceuticals (2014-2015), StemCells Inc. (2010-2016) and Ablexis as chairman (2010-2016). No current outside public board in the 2026 proxy biosrc
- Legal Named defendant, with Nektar and two scientists, in a securities class action over 2017-2018 statements on bempegaldesleukin trial data; dismissed, and the Ninth Circuit affirmed the dismissal on 2022-05-19src
- Other Recommends the other executives' pay and gives the board input on the corporate performance rating that sets his own bonus; he does not take part in deciding his own paysrc
Sources11
- Filing Nektar Therapeutics DEF 14A for the 2026-06-04 annual meeting (accession 0001140361-26-016708) · 2026-04-24
- Filing Nektar Therapeutics DEF 14A, 2021 (accession 0001193125-21-143681) · 2021-04-30
- Filing Nektar Therapeutics 10-K for FY2025 (accession 0001193125-26-104547) · 2026-03-13
- Filing Nektar Therapeutics 8-K Item 5.07, 2026 annual meeting results (0001213900-26-065845) · 2026-06-05
- Filing SEC XBRL companyconcept us-gaap/NetIncomeLoss, CIK 906709 (FY2025 10-K, 0001193125-26-104547) · 2026-03-13
- Filing Form 4, Howard W. Robin (reporting CIK 1206869), 10b5-1 sales of 2026-06-16/17 (0001193125-26-276236) · 2026-06-18
- Filing Form 4, Howard W. Robin, vesting of 2024 performance options on the Phase 3 start criterion (0001193125-26-316457) · 2026-07-24
- Filing Form 4, Howard W. Robin, vesting of 2020 performance RSUs/options and tax-withholding sale (0001193125-25-297850) · 2025-11-25
- Filing Form 4, Howard W. Robin, 10b5-1 sales of 2025-09-09 (0000950170-25-114365); earlier September sales on 0000950170-25-113129 and -113691 · 2025-09-11
- Web search result WebSearch: Howard W. Robin Nektar biography (search summary of Nektar leadership / press pages listing his former outside boards) · 2026-09-25
- Web search result WebSearch: In re Nektar Therapeutics, Ninth Circuit affirms dismissal of securities class action (Cooley) · 2026-09-25